文献类型：期刊文献

中文题名：虫草抗痨胶囊配合化疗治疗继发性肺结核614例回顾性分析

英文题名：A Retrospective Analysis of Cordyceps Anti-Tuberculosis Capsule Combined with Chemotherapy for 614 Cases of Secondary Tuberculosis

作者：王园[1,2];戴恩来[1];贾忠[3]

第一作者：王园

机构：[1]甘肃中医学院中两医结合系,甘肃省兰州市730000;[2]兰州市第一人民医院;[3]兰州市肺科医院

第一机构：甘肃中医药大学中西医结合学院

年份：2013

卷号：54

期号：15

起止页码：1304

中文期刊名：中医杂志

外文期刊名：Journal of Traditional Chinese Medicine

收录：CSTPCD;;北大核心:【北大核心2011】；CSCD:【CSCD2013_2014】；

语种：中文

中文关键词：虫草抗痨胶囊;肺结核;肺痨

外文关键词：Cordyceps Anti-Tuberculosis Capsule; tuberculosis

摘要：目的观察虫草抗痨胶囊辅助化疗治疗继发性肺结核的临床疗效。方法回顾性收集继发性肺结核患者1205例,将单纯采用化疗方案治疗者作为对照组(591例),在对照组基础上加服虫草抗痨胶囊者作为治疗组(614例)。两组初治患者治疗6个月、复治患者治疗9个月,统计疗效及病灶吸收情况、主要临床症状改善情况、痰菌阴转情况,并比较治疗前后两组T淋巴细胞亚群CD3+、CD4+、CD8+及CD4+/CD8+水平。结果治疗组总有效率94%;对照组总有效率79%,治疗组临床疗效优于对照组(P<0.05)。咳嗽咯痰、发热、胸痛、盗汗/乏力/咯血治疗组改善率分别为93.6%、86.6%、76.0%、95.8%;对照组分别为61.3%、53.9%、50.0%、68.5%,治疗组患者主要症状改善情况均优于对照组(P<0.05或P<0.01)。治疗组肺部病灶总吸收率、痰菌阴转率均高于对照组(P<0.05)。与对照组治疗后比较,治疗组CD3+、CD4+和CD4+/CD8+值均显著升高,CD8+值显著降低(P<0.05或P<0.01)。结论虫草抗痨胶囊配合化疗具有促进继发性肺结核患者结核病灶的吸收、提高患者痰涂片转阴率、改善症状、增强机体免疫力的作用,其疗效优于单纯西药治疗。
Objective To observe the therapeutic effect of Cordyceps Anti-Tuberculosis Capsule combined with chemotherapy on secondary tuberculosis （TB）. Methods Totally 1 205 cases of secondary TB were retrospectively collected. The patients who received chemotherapy were chosen as the control group including 591 cases. The patients who received chemotherapy and Cordyceps Anti-Tuberculosis Capsule were chosen as the treatment group including 614 cases. The naive patients and retreatment patients were treated for 6 months and 9 months respectively in both groups. The efficacy, focus absorption, improvement of main clinical symptoms and sputum conversion were observed. The level of T lymphocyte subsets CD3＋, CD4＋, CD8＋ and CD4＋/CD8＋ were compared in both groups before and after treatment. Results The total effective rate of the treatment group and control group was 94% and 79% respectively, with a significant difference between groups （P0.05）. The efficacy of cough, expectoration, fever, chest pain and night sweats or fatigue or hemoptysis in the treatment group was 93.6%, 86.6%, 75.8% and 96.3% respectively. The efficacy of cough, expectoration, fever, chest pain, night sweats, fatigue and hemoptysis in the control group was 61.3%, 53.9%, 50.0% and 68.5% respectively. The major symptom improvement in the treatment group was superior to that in the control group （P0.05 or P0.01）. The total absorption rate of lung lesions and sputum conversion rate in the treatment group was significantly higher than that in the control group （P0.05）. Comparing with the control group after treatment, the level of CD3＋, CD4＋ and CD4＋/CD8＋ were significantly increased but the CD8＋ value was significantly decreased in the treatment group （P0.05 or P0.01）. Conclusion The Cordyceps Anti-Tuberculosis Capsule combined with chemotherapy can promote the focus absorption, increase the sputum conversion rate, improve symptoms and enhance the immunity in secondary TB patients, with a better therapeutic effect as compared with western medicine.